Cotinga Pharmaceuticals (TSX-V: COT) (OTCQB: COTQF) is a clinical-stage pharmaceutical company that uses proprietary artificial intelligence (“AI”) technologies to pursue a targeted and transformational method to treating cancer and other unmet medical needs. Cotinga’s CHEMSAS® technology fast-tracks the discovery and development of novel drug therapies. The company’s lead compound, COTI‐2, has demonstrated in preclinical data that it could potentially improve the treatment of cancers with mutations in the p53 gene. COTI‐2 is being evaluated for the treatment of gynecologic cancers and HNSCC in a phase 1 clinical trial. Cotinga has secured orphan drug status in the United States for COTI‐2 for the treatment of ovarian cancer. COTI-219, the company’s second lead compound, is a novel oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS function. COTI-219 is undergoing IND-enabling studies to support a regulatory submission in 2018. For more information, visit the company’s website at www.cotingapharma.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
